Research into the gut-muscle axis finds some interesting connections between the role of inflammation and gut microbiota in the development of muscle failure in older populations.
The implications is also relevant in more general terms because of the role of gut microbiota (GM), probiotic supplementation, and the impact on muscular development.
Research into the gut-muscle axis finds some interesting connections between the role of inflammation and gut microbiota in the development of muscle failure in older populations.
The implications is also relevant in more general terms because of the role of gut microbiota (GM), probiotic supplementation, and the impact on muscular development.
GM is a universe of bacteria, billions upon billions of varieties, and more than a thousand species of fungi, viruses, phages, parasites, and archea in your gastrontestinal tract.
GM is recognized as playing a part in healthy absorption of nutrients in the gut, as well as providing immunity from infections, among other benefits. In the study summarized below, the researchers were studying the loss of muscle mass and strength as we age which is extenuated by inflammation and conditions such as inflammatory bowel disease (IBD).
The gut-muscle axis hypothesis is based on the notion that inflammation, imbalances in gut bacteria, and malnutrition are partially responsible for muscle failure in IBD patients, specifically, and as a general rule.
The figure above shows the key drivers in the development of the gut-muscle axis. What we know is that this axis is an interesting area of research and that it leads us to understanding how GM supplementation can lead to better muscle function.
So, while the study is specific to a clinical condition, it doesn’t change the biological implications. Metabolic processes, oxidative stress, and mitochondria functions are associated with GM, as is immune response.
The benefits of probiotic supplementation to improve muscle mass and function is going to be interesting to study and observe. It is primarily an issue of general health but could lead to improvements in performance-enhancement interventions in
Summary
Title: Inflammatory Bowel Diseases and Sarcopenia: The Role of Inflammation and Gut Microbiota in the Development of Muscle Failure
Date: February 25th, 2021
DOI: 10.3389/fimmu.2021.694217
Abstract: Sarcopenia represents a major health burden in industrialized country by reducing substantially the quality of life. Indeed, it is characterized by a progressive and generalized loss of muscle mass and function, leading to an increased risk of adverse outcomes and hospitalizations. Several factors are involved in the pathogenesis of sarcopenia, such as aging, inflammation, mitochondrial dysfunction, and insulin resistance. Recently, it has been reported that more than one third of inflammatory bowel disease (IBD) patients suffered from sarcopenia. Notably, the role of gut microbiota (GM) in developing muscle failure in IBD patient is a matter of increasing interest. It has been hypothesized that gut dysbiosis, that typically characterizes IBD, might alter the immune response and host metabolism, promoting a low-grade inflammation status able to up-regulate several molecular pathways related to sarcopenia. Therefore, we aim to describe the basis of IBD-related sarcopenia and provide the rationale for new potential therapeutic targets that may regulate the gut-muscle axis in IBD patients.
Main Purpose: Focuses on the key players in the gut-muscle axis.
Research Type: Literature review.
Findings Indicate: The gut-muscle axis is an interesting area of resaerch. An understanding of the pathophysiology of the gut-muscle axis in this instance is related to the association of GM supplementation as a treatment for IBD and related improvements in muscle mass and muscle funcion.
Limitation: The paper does not appear to have any limitations as such.
